Peptides for vision protection — glaucoma, macular degeneration, and dry eye

Vision loss carries a particular kind of dread because so much of what makes life recognizable — faces, reading, driving, landscape — runs through it. The conditions that threaten vision in midlife and beyond share a frustrating feature: most of them progress silently until a meaningful amount of function has already been lost. Glaucoma is sometimes called "the silent thief of sight." Dry age-related macular degeneration progresses slowly enough that many people don't notice until it affects the central vision they rely on. Dry eye, the most common midlife eye complaint, announces itself constantly — burning, gritty, foreign-body sensation, paradoxical tearing — but is rarely taken as seriously as it should be given its impact on quality of life and, over time, on corneal surface health.

Glaucoma involves two interacting components: intraocular pressure (IOP) that damages the optic nerve, and a neuropathic component in which retinal ganglion cells — the neurons whose axons form the optic nerve — are lost in ways that don't always track perfectly with pressure. Normal-tension glaucoma exists: optic nerve damage progresses despite IOP in the statistically normal range, implicating vascular insufficiency, oxidative stress, and neuronal vulnerability as contributors independent of pressure. This neurodegeneration angle is where the peptide research enters.

Age-related macular degeneration affects the macula — the central region of the retina responsible for high-acuity vision. Dry AMD involves the gradual accumulation of drusen (extracellular debris) and atrophy of the retinal pigment epithelium; it progresses slowly and currently has limited treatment options though complement inhibitors have recently been approved for geographic atrophy. Wet AMD involves the growth of abnormal blood vessels beneath the retina that leak and bleed; it progresses rapidly and, without treatment, causes severe central vision loss. Anti-VEGF injections — ranibizumab, bevacizumab used off-label, aflibercept — transformed wet AMD treatment and are highly effective at preserving vision when administered consistently. Diabetic retinopathy follows a similar anti-VEGF treatment logic for the proliferative and edematous components.

Dry eye disease is more complicated than it sounds. It's not simply insufficient tear production. It's a multifactorial disease of the ocular surface involving tear film instability, hyperosmolarity, ocular surface inflammation, and in many cases dysfunction of the meibomian glands — the oil-secreting glands of the eyelid whose output forms the lipid layer that prevents aqueous evaporation. Hormone changes in perimenopause and menopause significantly worsen dry eye, as do screen use, contact lens wear, certain medications (antihistamines, antidepressants, diuretics), and autoimmune conditions like Sjögren's syndrome. The conventional treatment hierarchy includes artificial tears for mild cases; anti-inflammatory drops (cyclosporine ophthalmic emulsion, lifitegrast) for moderate to severe disease; punctal plugs to reduce tear drainage; intense pulsed light and thermal expression for meibomian gland dysfunction; and autologous serum tears derived from the patient's own blood for severe cases and those with surface damage.

The peptide research landscape for vision is early but has some genuinely interesting threads.

PACAP — pituitary adenylate cyclase-activating polypeptide — has attracted preclinical attention for retinal neuroprotection that maps directly onto glaucoma's neurodegeneration component. In animal models of glaucoma and optic nerve injury, PACAP administration has shown protective effects on retinal ganglion cells — the specific neurons lost in glaucoma. The mechanisms are several: PACAP reduces retinal inflammation, activates anti-apoptotic signaling in stressed neurons, and has mitochondrial protective effects that may be relevant to the energy failure underlying retinal ganglion cell death. Intravitreal PACAP research in animal models has shown meaningful preservation of retinal ganglion cell density and retinal function. The translation to human clinical use faces the same delivery challenges that characterize PACAP research broadly — it does not cross biological barriers easily, making delivery route a significant obstacle. Topical and intravitreal approaches are under investigation. PACAP is not FDA-approved for any ophthalmic indication.

Thymosin Beta-4 occupies a more clinically advanced position than most peptides in this space for the specific indication of corneal injury and dry eye. RegeneRx Biopharmaceuticals ran a clinical program exploring TB4 ophthalmic solution (RGN-259) for dry eye and neurotrophic keratopathy — a condition in which reduced corneal nerve sensitivity impairs healing and tear production. Phase 2 trial data showed improvements in both objective measures (corneal healing) and patient-reported symptoms in dry eye patients. The program has not resulted in an FDA approval as of this writing, but the clinical trial work here is more advanced than the preclinical-only evidence that characterizes most of this space. TB4's mechanism in the eye involves corneal wound healing, anti-inflammatory effects, and support of the complex neural-epithelial relationship that governs corneal surface health and tear film stability. For people with severe dry eye, neurotrophic keratopathy, or recurrent corneal erosions, the TB4 research trajectory is worth following with an ophthalmologist who tracks the literature.

Retinalamin is a retina-specific bioregulatory peptide from the Khavinson peptide tradition — a family of organ-specific peptide fractions developed in Russia based on the principle that tissue-specific peptides have preferential cytoprotective effects in their tissue of origin. Retinalamin is derived from bovine retina and has been used clinically in Russia for conditions including dry AMD, diabetic retinopathy, and open-angle glaucoma. Some published studies from Russian groups report improvements in visual acuity and electroretinographic parameters. By Western clinical trial standards, the evidence base doesn't meet approval thresholds, and the peptide is not FDA-approved. The tradition it comes from is scientifically coherent in its mechanistic reasoning even where the trial designs are not sufficient for Western regulatory bodies.

Cerebrolysin has appeared in some retinal research contexts, particularly in connection with optic nerve and retinal neuroprotection following ischemic events. The neurotrophic-factor-like activity that characterizes Cerebrolysin's proposed mechanism in brain conditions has some applicability to retinal ganglion cells, which are CNS neurons. This is a peripheral thread in the Cerebrolysin research literature rather than a primary focus.

Humanin and NAD+ belong to the broader neuroprotection picture that includes retinal neurons. The retina is neural tissue — it is embryologically an extension of the brain — and the mitochondrial support mechanisms relevant to neurodegeneration generally are relevant to retinal aging and neuroprotection specifically. Retinal pigment epithelial cells are among the most metabolically demanding cells in the body; mitochondrial dysfunction is a recognized contributor to AMD pathogenesis. The mechanistic rationale for mitochondrial support is solid; the clinical translation to vision preservation specifically is not yet established.

GHK-Cu in periocular contexts appears primarily in the anti-aging skin literature — the periorbital area being one of the earliest sites of visible skin aging — rather than in intraocular or retinal research. Its role in supporting extracellular matrix synthesis and its anti-inflammatory properties have periocular skin relevance; it is not a retinal or optic nerve agent.

The conventional ophthalmology hierarchy for the conditions discussed here carries enormous weight. Glaucoma is one of the clearest examples of a condition where missing or delaying treatment has irreversible consequences — damaged retinal ganglion cells are gone, the axons don't regenerate, the visual field loss is permanent. IOP-lowering drops (prostaglandin analogs, beta-blockers, alpha-agonists, carbonic anhydrase inhibitors) are highly effective and well-tolerated; laser trabeculoplasty and glaucoma surgery are available when drops are insufficient. The monitoring cadence — regular visual field testing, optic nerve imaging — is how silent progression gets caught and responded to. Anti-VEGF injections for wet AMD are among the biggest treatment advances in ophthalmology in the last twenty years; consistent adherence to the injection schedule determines outcomes in a way that cannot be supplemented around. For dry eye, cyclosporine and lifitegrast address the inflammation that drives the condition rather than just masking symptoms.

The role of foundational health in vision preservation is increasingly well-documented. Cardiovascular fitness, blood pressure control, and glycemic control are directly relevant to vascular AMD, diabetic retinopathy, normal-tension glaucoma, and vascular contributions to optic nerve health. The AREDS and AREDS2 supplement formulation — vitamins C and E, zinc, copper, lutein and zeaxanthin — has level-one evidence for slowing progression of intermediate to advanced AMD; it doesn't prevent AMD and doesn't help early AMD, but for people with appropriate staging it is one of the few supplement interventions with genuine clinical trial support in any vision indication. Lutein and zeaxanthin are found in leafy greens and eggs; dietary abundance matters.

Vision is not a domain for experimentation without specialist oversight. The reason ophthalmologic care is non-negotiable — not optional, not something to work around, not a thing to delay while trying peptide approaches — is the irreversibility of what happens when intervention comes late. Retinal ganglion cells don't regenerate. Central vision lost to AMD doesn't return. Even a compound like TB4, with its clinical trial trajectory, was studied in the context of rigorous ophthalmologic monitoring. The peptide research in vision protection is genuinely interesting and may eventually produce clinical tools that complement conventional care. That complement relationship — adjunctive, monitored, coordinated — is the only responsible frame for this biology. An ophthalmologist who knows your condition, your imaging, your disease trajectory, and the state of the emerging literature is the right person to think through any of these approaches with. The eye is too precious and too unforgiving of delay to approach any other way.